Dulcan i Lake 2011 ↓, s.34.
Mina K.M.K.DulcanMina K.M.K., MaryBethM.LakeMaryBethM., Concise Guide to Child and Adolescent Psychiatry, Washington, D.C.: American Psychiatric Publishing, 1 czerwca 2011, ISBN978-1-58562-416-4(ang.).
Faraone 2011 ↓, s.449–450.
Stephen V.S.V.FaraoneStephen V.S.V., 25: Epidemiology of attention deficit hyperactivity disorder, [w:] MingM.Tsuang, MauricioM.Tohen, Peter B.P.B.Jones (red.), Textbook of psychiatric epidemiology, wyd. 3, Chichester, West Sussex: John Wiley & Sons, 2011, ISBN978-0-470-97740-8.
Prifitera, Saklofske i Weiss 2005 ↓, s.237.
AurelioA.PrifiteraAurelioA., Donald H.D.H.SaklofskeDonald H.D.H., Lawrence DavidL.D.WeissLawrence DavidL.D., WISC-4 Clinical Use and Interpretation, Academic Press, 2005, ISBN978-0-12-564931-5(ang.).
Childress i Berry 2012 ↓, s.309–325.
Ann C.A.C.ChildressAnn C.A.C., Sally A.S.A.BerrySally A.S.A., Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents, „Drugs”, 3 (72), 2012, DOI:10.2165/11599580-000000000-00000(ang.).
Erik G.E.G.WillcuttErik G.E.G., The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review, „Neurotherapeutics”, 9 (3), 2012, s. 490–499, DOI:10.1007/s13311-012-0135-8, ISSN1878-7479 [dostęp 2024-01-28].
Huang i Tsai 2011 ↓, s.539–554.
Yu-ShuY.S.HuangYu-ShuY.S., Ming-HorngM.H.TsaiMing-HorngM.H., Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge, „CNS Drugs”, 25 (7), 2011, s. 539–554, DOI:10.2165/11589380-000000000-00000, PMID:21699268.
Burt 2009 ↓, s.608–637.
Alexandra S.A.S.BurtAlexandra S.A.S., Rethinking environmental contributions to child and adolescent psychopathology: a meta-analysis of shared environmental influences, „Psychological Bulletin”, 135 (4), 2009, s. 608–637, DOI:10.1037/a0015702, PMID:19586164.
Gizer, Ficks i Waldman 2009 ↓, s.51–90.
Ian R.I.R.GizerIan R.I.R., CourtneyC.FicksCourtneyC., Irwin D.I.D.WaldmanIrwin D.I.D., Candidate gene studies of ADHD: a meta-analytic review, „Human Genetics”, 126 (1), 2009, s. 51–90, DOI:10.1007/s00439-009-0694-x(ang.).
Berry 2007 ↓, s.3–19.
M.D.M.D.BerryM.D.M.D., The potential of trace amines and their receptors for treating neurological and psychiatric diseases, „Reviews on Recent Clinical Trials”, 2 (1), 2007, s. 3–19, DOI:10.2174/157488707779318107, PMID:18473983.
Glover 2011 ↓, s.356–367.
VivetteV.GloverVivetteV., Annual Research Review: Prenatal stress and the origins of psychopathology: an evolutionary perspective, „Journal of Child Psychology and Psychiatry, and Allied Disciplines”, 52 (4), 2011, s. 356–367, DOI:10.1111/j.1469-7610.2011.02371.x, PMID:21250994.
Grimm O, Kittel-Schneider S, Reif A.Recent developments in the genetics of attention-deficit hyperactivity disorder.„Psychiatry Clin Neurosci”.72(9),s.654–672,2018. DOI: 10.1111/pcn.12673.
Maren Johanne HeilskovM.J.H.RytterMaren Johanne HeilskovM.J.H. i inni, Diet in the treatment of ADHD in children – A systematic review of the literature, „Nordic Journal of Psychiatry”, 69(1), 2015, s. 1–18, DOI:10.3109/08039488.2014.921933.
Annelies A.J.A.A.J.VerlaetAnnelies A.J.A.A.J., Daniela BricenoD.B.NoriegaDaniela BricenoD.B., NinaN.HermansNinaN., Huub F.J.H.F.J.SavelkoulHuub F.J.H.F.J., Nutrition, immunological mechanisms and dietary immunomodulation in ADHD, „European Child & Adolescent Psychiatry”, 23(7), 2014, s. 519–529, DOI:10.1007/s00787-014-0522-2.
Joel T.J.T.NiggJoel T.J.T., KaraK.LewisKaraK., TracyT.EdingerTracyT., MichaelM.FalkMichaelM., Meta-Analysis of Attention-Deficit/Hyperactivity Disorder or Attention-Deficit/Hyperactivity Disorder Symptoms, Restriction Diet, and Synthetic Food Color Additives, „Journal of American Academy of Child and Adolescent Psychiatry”, 51(1), 2012, s. 86–97, DOI:10.1016/j.jaac.2011.10.015.
Bálint i in. 2008 ↓, s.324–335.
SáraS.BálintSáraS., PálP.CzoborPálP., AgnesA.MészárosAgnesA., ViktóriaV.SimonViktóriaV., IstvánI.BitterIstvánI., Neuropszichológiai károsodásokat felnőtt figyelemhiányos hiperaktivitás zavar(ADHD): A szakirodalmi áttekintés (Neuropsychological impairments in adult attention deficit hyperactivity disorder: a literature review), „Psychiatria Hungarica: A Magyar Pszichiátriai Társaság Tudományos Folyóirata”, 5 (23), 2008, s. 324–335, PMID:19129549(węg.).
Huang i Tsai 2011 ↓, s.539–554.
Yu-ShuY.S.HuangYu-ShuY.S., Ming-HorngM.H.TsaiMing-HorngM.H., Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge, „CNS Drugs”, 25 (7), 2011, s. 539–554, DOI:10.2165/11589380-000000000-00000, PMID:21699268.
Burt 2009 ↓, s.608–637.
Alexandra S.A.S.BurtAlexandra S.A.S., Rethinking environmental contributions to child and adolescent psychopathology: a meta-analysis of shared environmental influences, „Psychological Bulletin”, 135 (4), 2009, s. 608–637, DOI:10.1037/a0015702, PMID:19586164.
Berry 2007 ↓, s.3–19.
M.D.M.D.BerryM.D.M.D., The potential of trace amines and their receptors for treating neurological and psychiatric diseases, „Reviews on Recent Clinical Trials”, 2 (1), 2007, s. 3–19, DOI:10.2174/157488707779318107, PMID:18473983.
Cardo i in. 2010 ↓, s.143–147.
E.E.CardoE.E., A.A.NevotA.A., M.M.RedondoM.M., A.A.MeleroA.A., B. deB.AzuaB. deB., Trastorno por déficit de atención/hiperactividad: ¿un patrón evolutivo?, „Revista De Neurologia”, 50 suppl. 3, 2010, s. 143–147, PMID:20200842(hiszp.).
Glover 2011 ↓, s.356–367.
VivetteV.GloverVivetteV., Annual Research Review: Prenatal stress and the origins of psychopathology: an evolutionary perspective, „Journal of Child Psychology and Psychiatry, and Allied Disciplines”, 52 (4), 2011, s. 356–367, DOI:10.1111/j.1469-7610.2011.02371.x, PMID:21250994.
Zavadenko i Suvorinova 2004 ↓, s.32–37.
N.N.N.N.ZavadenkoN.N.N.N., N.Û.N.Û.SuvorinovaN.Û.N.Û., Терапевтическое действие разных доз ноотропила при синдроме дефицита внимания с гиперактивностью у детей, „Журнал неврологии и психиатрии имени С. С. Корсакова [Žurnal nevrologii i psihiatrii imeni S. S. Korsakova]”, 3 (104), tytuł angielski: Therapeutic efficacy of nootropil different doses in attention deficit hyperactivity disorder, Moskva: Ministerstvo Zdravookhraneniia i Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov, Vserossiĭskoe Obshchestvo Psikhiatrov, 2004, s. 32–37, ISSN1997-7298, PMID:15071842(ros.•ang.).
Erik G.E.G.WillcuttErik G.E.G., The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review, „Neurotherapeutics”, 9 (3), 2012, s. 490–499, DOI:10.1007/s13311-012-0135-8, ISSN1878-7479 [dostęp 2024-01-28].
Zavadenko i Suvorinova 2004 ↓, s.32–37.
N.N.N.N.ZavadenkoN.N.N.N., N.Û.N.Û.SuvorinovaN.Û.N.Û., Терапевтическое действие разных доз ноотропила при синдроме дефицита внимания с гиперактивностью у детей, „Журнал неврологии и психиатрии имени С. С. Корсакова [Žurnal nevrologii i psihiatrii imeni S. S. Korsakova]”, 3 (104), tytuł angielski: Therapeutic efficacy of nootropil different doses in attention deficit hyperactivity disorder, Moskva: Ministerstvo Zdravookhraneniia i Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov, Vserossiĭskoe Obshchestvo Psikhiatrov, 2004, s. 32–37, ISSN1997-7298, PMID:15071842(ros.•ang.).
Nestler, Hyman i Malenka 2008 ↓, s.313–321.
EricE.NestlerEricE., StevenS.HymanStevenS., RobertR.MalenkaRobertR., Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, Second Edition, wyd. 2, McGraw Hill professional, New York: McGraw-Hill Medical, 27 października 2008, ISBN978-0-07-148127-4, OCLC273018757(ang.).